Prostate Cancer Coverage from Every Angle
Editor:
Sandy Srinivas, MD
Advertisement
Advertisement

News

DLL3-Targeting T-Cell Engager Under Study in Neuroendocrine Prostate Cancer
More FORMULA-509 Results After Radical Prostatectomy: Quality-of-Life Outcomes
Long-Term Outcomes Support Image-Guided Therapy for Localized Prostate Cancer
Impact of Metastatic Site on the Genomic, Transcriptomic, and Immune Landscape of Prostate Cancer
Predicting Clinically Significant Prostate Cancer in a Multiethnic Cohort: Novel Blood Assay vs PSA Levels
Combination Therapy Under Study in Metastatic Prostate Cancer With HRR Mutations
Antibiotic Stewardship: Transperineal vs Transrectal Prostate Biopsy
Phase III Trial of Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2024: Cognitive Function With Abiraterone vs Enzalutamide in Metastatic Prostate Cancer
ASCO GU 2024: Dose-Escalation vs Conventional Radiotherapy in High-Risk Prostate Cancer
ASCO GU 2024: Suspending Enzalutamide Monotherapy in High-Risk, Biochemically Recurrent Prostate Cancer
Society of Women in Urologic Oncology Elects Inaugural Chair
Does Adding Radium-223 to Third-Line Therapy Offer Survival Benefit in Metastatic Prostate Cancer?
SUO 2023: Toxicity Trends With Radioligand Therapy for Prostate Cancer
SUO 2023: Is Radioligand Therapy Safe for Patients With Prostate Cancer and Baseline Cytopenia?
Understanding Men’s Communication Preferences When Discussing Prostate Cancer Screening
FDA Approves Expanded Enzalutamide Indication for High-Risk Nonmetastatic Prostate Cancer
PARP Inhibitors and Prostate Cancer: Perceptions of Surveyed Practicing Oncologists
Alone or With Leuprolide, Enzalutamide May Help to Stop Spread of Prostate Cancer
ESMO 2023: Pembrolizumab Plus Enzalutamide Therapy Metastatic Prostate Cancer
ESMO 2023: New Insight on Treating High-Risk Prostate Cancer From 30 Years of Data
Can Radiotherapy Prime Immune System in Oligometastatic Prostate Cancer?
ESMO 2023: Does Adjuvant Radiotherapy Offer Benefit After Radical Prostatectomy?
ESMO 2023: Phase II Results With Enzalutamide Plus Radioligand Therapy in Prostate Cancer
ESMO 2023: Early Results With Novel Bispecific Antibody in Metastatic Prostate Cancer
Conventional Versus Stereotactic Proton Therapy for Early-Stage Prostate Cancer
ASTRO 2023: Disease Progression–Directed Therapy May Postpone Next-Line Treatment of Oligoprogressive Prostate Cancer
ESMO 2023: Is There a Role for Adjuvant Radiotherapy After Radical Prostatectomy?
Copyright © 2024 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.